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Abstract: The rise in prevalence of obesity in women of reproductive age in developed and develop-
ing countries might propagate intergenerational cycles of detrimental effects on metabolic health.
Placental lipid metabolism is disrupted by maternal obesity, which possibly affects the life-long health
of the offspring. Here, we investigated placental lipid metabolism in women with pre-gestational
obesity as a sole pregnancy complication and compared it to placental responses of lean women.
Open profile and targeted lipidomics were used to assess placental lipids and oxidised products of
docosahexaenoic (DHA) and arachidonic acid (AA), respectively, neuroprostanes and isoprostanes.
Despite no overall signs of lipid accumulation, DHA and AA levels in placentas from obese women
were, respectively, 2.2 and 2.5 times higher than those from lean women. Additionally, a 2-fold
increase in DHA-derived neuroprostanes and a 1.7-fold increase in AA-derived isoprostanes were
seen in the obese group. These changes correlated with a 70% decrease in placental FABP1 protein.
Multivariate analyses suggested that neuroprostanes and isoprostanes are associated with maternal
and placental inflammation and with birth weight. These results might shed light on the molecular
mechanisms associated with altered placental fatty acid metabolism in maternal pre-gestational
obesity, placing these oxidised fatty acids as novel mediators of placental function.
Keywords: maternal pre-gestational obesity; placenta; lipid metabolism; fatty acid transporter
proteins; isoprostanoids; neuroprostanes; isoprostanes; docosahexaenoic acid; arachidonic acid
Nutrients 2021, 13, 2768. https://doi.org/10.3390/nu13082768 https://www.mdpi.com/journal/nutrients
Nutrients 2021, 13, 2768 2 of 18
1. Introduction
Maternal pre-gestational obesity and excessive gestational weight gain affect short-
and long-term health of both the mother and her child [1]. Gestational diabetes mellitus
and pre-eclampsia are complications of pregnancy associated with gestational obesity,
and newborns from obese women have an increased risk of overgrowth. Obesity in
adults and in children has reached epidemic proportions in Brazil [2] and worldwide [3].
Therefore, the rise in prevalence of obesity in women of reproductive age in both developed
and developing countries might propagate intergenerational cycles of detrimental effects
on metabolic health, contributing to substantial economic burden on society [4–7] and
highlighting the necessity of determining the mechanisms involved.
Fatty acids are essential for the accretion of body fat in the fetus, especially during
the last trimester of pregnancy. Long chain polyunsaturated fatty acids, in particular
docosahexaenoic acid (DHA) and arachidonic acid (AA), have specific roles in membrane
composition and the development of the retina, and are the major components of the white
matter of the brain. Therefore, they are of paramount importance to proper neural and
visual development and cognitive function [8–11]. Ex vivo placental perfusion data [12] and
in vivo kinetics of 13C-fatty acids [13] show that maternal–fetal 13C-labelled lipid transfer is
very low (1–6%), implying that lipid metabolism and handling by the placenta are strictly
controlled and that these mechanisms are possibly major players in the allocation of fatty
acids to fetal organs [14,15].
The inflammatory milieu imposed by maternal obesity disrupts the cross-talk between
maternal signals and the placenta, resulting in impaired placental function [16]. Uptake
and metabolism of essential fatty acids, particularly DHA, is impaired in placentas from
obese women [17,18]. Increased accumulation of lipids in the placenta has been described
in gestational obesity, which was associated with decreased oxidation of fatty acids and
impaired mitochondrial function [19,20]. Conversely, other studies have reported that
placental total lipid content [21] and maternal–fetal transfer of 13C-labelled non-essential
fatty acids [13] is similar between lean and obese mothers. Altogether, these observations
emphasize that placental lipid handling and metabolism might be disrupted by maternal
obesity and deserve further investigation to clarify the mechanisms involved.
The maternal circulation, and ultimately the maternal diet, are the sources of polyun-
saturated fatty acids, as their synthesis by the fetus and the placenta is limited and in-
sufficient to meet the high demand imposed by the growing fetus. Placental fatty acid
handling relies on several proteins which are responsible for (a) the uptake of fatty acids
from the maternal circulation, partly as lipoproteins and as non-esterified fatty acids and
lysophospholipids bound to albumin, and (b) the numerous metabolic fates of fatty acids
and also their transfer to the fetus [22]. The hydrolysis of fatty acids from triacylglycerol
in lipoproteins is catalyzed by endothelial lipase and by lipoprotein lipase. The former is
selective for hydrolyzing unsaturated fatty acids esterified in the sn-2 position of glycerol.
Fatty acids are then taken up by the placenta by fatty acid translocators (FAT/CD36), fatty
acid transport proteins (FATP/SLC27A), and Mfsd2a. In the cytoplasm of the syncytiotro-
phoblast, fatty acid binding proteins (FABPs), which are noncatalytic binding proteins,
mediate fatty acid metabolism and inflammatory processes [23].
Both the expression and the content of placental fatty acid transport proteins are
altered by maternal obesity [19,24–26]. However, how these changes affect placental
fatty acid metabolism and signalling properties, and fatty acid transport and availability
to the fetus in maternal gestational obesity, is not fully understood. Oxidative stress
and inflammation have been associated with enhanced contents of oxidised fatty acids
and trophoblast dysfunction in pre-eclampsia. In particular, hydroxyeicosatetraenoic
acids (HETEs), products of AA oxidation catalyzed by lipoxygenases and CYP, and F2-
isoprostanes, products of non-enzymatic peroxidation of AA, are increased in placentas
from pregnancies complicated by pre-eclampsia [27,28]. All these fatty acid metabolites
have some degree of vasoconstrictive and pro-inflammatory effects and so may affect
placental function.
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Here, we characterized the major categories and classes of lipids in term placentas from
pregnancies complicated by maternal pre-gestational obesity. We also analysed fatty acid
transport proteins involved in the handling of polyunsaturated fatty acids by the placenta.
A novel aspect of this study was a thorough characterization of placental non-enzymatically
oxidised isoprostanoids derived from AA and DHA, which as inflammatory mediators
might be a mechanistic link between pre-gestational obesity and placental dysfunction.
Additionally, we assessed how polyunsaturated fatty acids and their oxidised fatty acids
metabolites are associated with inflammation and lipid handling by the placenta, and
possibly with neonatal outcomes in maternal pre-gestational obesity.
2. Materials and Methods
2.1. Study Design and Participants
The current study was part of a randomized controlled trial registered on clinicaltri-
als.org (NCT03215784), which was designed to evaluate the effects of fish oil and probiotics
supplementation throughout pregnancy on women with pre-gestational obesity. The study
was conducted at the Maternidade Escola, between January 2015 and July 2017. This is
a referral hospital, belonging to the Federal University of Rio de Janeiro, dedicated to
providing pre-natal and delivery care and puerperal consultations to the local community.
Women were recruited up to 13 weeks of pregnancy and the inclusion criteria were age
between 19–35 y, pre-gestational body mass index (BMI) between 18.5 and 24.9 kg/m2
(lean) or ≥30 and ≤40 kg/m2 (obesity class 1 and class 2; [29]), absence of pre-existing
infectious or chronic disease, except for obesity, a single fetus, and non-smoker. As a part
of the pre-natal care, women presenting with high-risk pregnancies received nutritional
counselling. Dietary intake was obtained during consultations in the 3rd trimester by
trained professionals (Supplementary File S1).
Gestational weight gain was classified accordingly [30] and gestational outcomes and
newborn information (weight and length at birth) were obtained from medical charts and
classified according to the INTERGROWTH-21st Project Curves [31].
To reduce possible confounders, we opted to only include samples from women who
did not develop gestational diabetes mellitus, pre-eclampsia, or other pregnancy com-
plications. Hence, maternal pre-gestational obesity was the sole associated complication.
Matched maternal blood, placental samples, and umbilical cord blood of 12 women (6 lean
and 6 obese) were used.
2.2. Ethics
Women read and signed a ‘Free and Informed Consent’ form upon recruitment, and
this study was approved by the local Ethics committee of the Maternidade Escola and
by the National Ethics committee (approval number CEP: 34611513.0.0000.5257 on 14
October 2014).
2.3. Biological Samples
Maternal blood was collected at the 36th gestational week and placental and umbilical
cord blood samples were collected at delivery. The time between delivery and collection
was up to 20–30 min. Umbilical cord blood was obtained by venipuncture and placental
tissue was collected according to established procedures [32]. Placental samples were taken
from the maternal surface, placed into cryovials, frozen immediately in liquid nitrogen, and
stored at −80 ◦C until analysis. A detailed description of placenta sampling is provided in
Supplementary File S1.
2.4. Chemical and Reagents
All standards used in the targeted isoprostanoids analyses were synthetized in house,
as published [33–37]. Internal standards: C19-16-F1t-PhytoP and C21-15-F2t-IsoP; External
standards: isoprostanes 15-F2t-IsoP, 15-epi-15-F2t-IsoP, 5-F2t-IsoP, and 5-epi-5-F2t-IsoP, and
neuroprostanes 10-F4t-NeuroP, 10-epi-10-F4t-NeuroP, and 4(RS)-4-F4t-NeuroP.
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2.5. Fatty Acid Transporter Proteins in Placental Tissue
2.5.1. Quantitative Real-Time PCR (qPCR)
qPCR was performed using TaqMan™ Universal PCR Master Mix (Applied Biosys-
tems, Thermo Fisher Scientific, Waltham, MA, USA) with the following primers from
TaqMan™ Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA: Hs00195812
(EL), Hs00155026 (FABP1), and Hs00997360 (FABP3). Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) was used as the housekeeping gene and transcripts were calculated
using the threshold cycle 2-∆∆CT method [38]. A detailed description of qPCR analysis is
available in Supplementary File S1.
2.5.2. Western Blotting
Primary antibodies for EL (MBS2013720) from My BioSource, Inc. (San Diego, CA,
USA), FABP1 (AB7366), and FABP3 (AB16916) from ABCAM (Cambridge, United King-
dom) were used in the following dilutions, respectively: 1:1000 EL, 1:500, and 1:500.
Loading control was performed with anti-β-actin antibody (Sigma-Aldrich, Saint Louis,
MO, USA, SAB5500001). A full description of Western blotting analysis is provided in
Supplementary File S1.
2.6. Cytokines in Plasma and Placental Tissue
Quantification of the cytokines (IL-1β: Interleukin-1β; IL-6: Interleukin-6; IL-10:
Interleukin-10; TNF-α: Tumour Necrosis Factor-α) in maternal plasma, umbilical cord
plasma, and placental tissue protein extract was performed by the Luminex xMAP (Multiple
Analytic Profiling, Thermo Fisher Scientific, Waltham, MA, USA) assay [39] using 100 µg
of placental extract as described for Western blotting analysis.
2.7. Maternal Lipoprotein Profile
Triglycerides, cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein
(HDL) were determined by enzymatic assay commercial kits (Sigma-Aldrich, Saint Louis,
MO, USA), and very-low density lipoprotein (VLDL) was estimated using the formula
proposed by Friedewald, Levy and Fredrickson (1972) [40].
2.8. Ion Mobility QTOF LC/MS Lipid Profile Analysis of Placenta Samples
Lipids were extracted using a modified Folch method [41]. The non-polar extract in
chloroform was dried under nitrogen and suspended in isopropanol:acetonitrile:water
(IPA:ACN:H2O, 2:1:1, v/v/v) containing 25 deuterated lipids used as internal standards
(representatives of phosphatidic acid, phosphatidylcholines, phosphatidylethanolamines,
glycerophospholipids, phosphatidylinositols, phosphatidylserine, sphingomyelin,
ceramides, triacylglycerols, and free fatty acids; Supplementary Table S1). All samples
were analysed in positive and negative modes.
An Agilent 6560 Ion Mobility Quadrupole Time-of-Flight (IM-QTOF) mass spectrome-
ter coupled with an Agilent 1290 UHPLC system was used to combine separation power
and selectivity of LC, IM, and MS techniques. The Dual Agilent Jet Stream Electrospray
Ionization Source was operated separately in positive and negative ion modes. The detailed
description of the LC-MS analyses can be found in Supplementary File S1.
Chromatogram Pre-Processing and Lipid Annotation
Data pre-processing, including mass and CCS re-calibration and feature finding, was
carried out using the packages IM-MS Reprocessor, IM-MS Browser and Mass Profiler from
the MassHunter suite vB.08.00 (Agilent Technologies, Santa Clara, CA, USA).
The resulting data matrices were processed using a KNIME pipeline comprising both
KNIME native nodes and integrated R scripts. Feature annotation was performed based
on the AccurateMassSearch node of the OpenMS library [42].
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2.9. Isoprostanoids in Placental Tissue
Isoprostanoids in placenta were determined based on a microLC–MS/MS method [43]
after lipid extraction by the Folch method [41], which were then mixed with a mixture of
internal standards, followed by alkaline hydrolysis. MS analysis was performed in an AB
Sciex QTRAP 5500 (AB Sciex, Framingham, MA, USA) with an electrospray ionization
source operated in negative mode. Quantification of isoprostanoids was performed with
the MultiQuant 3.0 software using specific internal standards. The detailed description of
isoprostanoids analysis by microLC–MS/MS is described in Supplementary File S1.
2.10. Statistical Analyses
Variables’ frequency distribution was assessed by standardized coefficients of skew-
ness and kurtosis. Those with values < −2.0 or > +2.0 were characterized as having a
non-normal distribution, and were then presented as median and interquartile interval, and
compared using the Mann–Whitney test. Groups’ frequency distributions were compared
using the chi-square test. Associations between continuous variables were assessed by
Spearman’s correlation analysis. Stepwise multiple regression analyses (backward) were
used to investigate the effect of independent factors on birth weight and on mothers and
placental tissue content of isoprostanoids. The criteria for the inclusion of independent
variables in the multiple regression models were based on results from Spearman corre-
lations and on biochemical soundness. In the final model, only significant variables that
improved the adjustment of the model were kept (p-to-remove ≥ 0.05; p-to-persist < 0.05).
The multiple regression models were further assessed by analysis of residual plots that were
checked to determine if they were randomly distributed. Data analyses were performed
with GraphPad Prism v7.0 (GraphPad Software, San Diego, CA, USA) and Statgraphics
Centurion v18 (Statgraphics Technologies, Inc.; The Plains, VA, USA). In all analyses,
p < 0.05 was considered for rejection of the null hypothesis.
3. Results
3.1. General Characteristics of the Mothers and Newborns
The general characteristics of the mothers included in this study, their gestational
outcomes and newborn information are presented in Table 1. Maternal pre-gestational BMI
was significantly higher in the obese group (p < 0.05) and the median BMI value indicates
obesity class I. Additionally, gestational weight gain was on average 40% lower in the obese
mothers than in the lean group. No differences were observed in all other measurements,
including gestational week at delivery, delivery mode and placental efficiency (weight at
birth:placental weight ratio). Newborn outcomes were also similar despite the higher pre-
gestational BMI in the obese group. Dietary records showed that there were no significant
differences in energy and carbohydrate, protein, and lipid intake between groups during
pregnancy (Supplementary Table S2). Therefore, the lower gestational weight gain observed
in obese women may be explained, in part, as a consequence of nutritional counselling.
3.2. Placental Lipid Profile Suggests Alterations in Long-Chain Polyunsaturated Fatty Acids
Abundance despite No Apparent Signs of Inflammation and Dyslipidemia in Maternal
Pre-Gestational Obesity
Annotated species were separated into the lipid categories glycerophospholipids, sph-
ingolipids, fatty acyls, glycerolipids, and sterols [44]. In both groups, glycerophospholipids
was the most abundant category corresponding to 70% of the annotated signals, followed by
sphingolipids (17%), fatty acyls (8%), glycerolipids (5%), and sterols (< 1%) (Figure 1A). No
differences were observed in any lipid categories between the lean and obese women. Glyc-
erophospholipids, sphingolipids, and glycerolipids were divided into classes. The most
abundant classes with biological significance are shown in Figure 1B. Total glycerophospho-
lipid was similar between the groups. However, the content of lysophospholipids tended
to a marginal (p = 0.056) 1.25-fold increase in placentas from obese women. Ceramides
and sphingomyelins were the most abundant sphingolipids that showed similar contents
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between groups. Lastly, contents of monoacylglycerol, diacylglycerol, and triacylglycerol
did not differ between the groups.
Table 1. Clinical characterization of the mothers and newborns participating in the study.
Mothers
Lean (n = 6) Obese (n = 6)
Maternal age (years) A 26.0 (19.0–32.0) 26.5 (20.0–31.0)
Maternal pre-gestational BMI (kg/m2) A 22.0 (19.0–24.2) 34.3 (31.2–37.6) *
Gestational weight gain (kg) A 11.6 (10.1–21.3) 6.6 (1.5–19.0)
Gestational age (weeks) 40.5 (38.0–41.0) 39.0 (38.0–41.0)
Complications of pregnancy
(other than pre-gestational obesity) none none
Delivery mode (n; %) vaginal (2; 33); c/s B (4; 66) vaginal (1; 17); c/s B (5; 83)
Newborn
Placental weight (g) A 485.0 (400.0–555.0) 480.0 (480.0–575.0)
Placental efficiency
(birth weight:placental weight ratio) 6.9 (6.1–10.0) 6.9 (6.4–7.4)
Birth weight (kg) A 3.3 (3.1–4.0) 3.4 (3.0–4.0)
Birth length (cm) A 49.5 (46.0–53.5) 48.5 (45.0–52.0)
A values expressed as median (minimum-maximum); * significantly different compared to lean women, p < 0.01,
Mann–Whitney test; B c/s, cesarean section.
Figure 1. Placental lipid profile suggests alterations in long-chain polyunsaturated free fatty acids abundance in maternal
pre-gestational obesity. Placental lipid profile was determined by IM-QTOF LC/MS after lipid extraction by the Folch
method. Ion intensities were processed using a KNIME pipeline comprising both KNIME native nodes and integrated R
scripts, and lipids were assigned into categories, classes, and species. Placentas from lean (•) and from obese (#) women
were compared according to (A) the abundance of lipid categories expressed relative to total lipid annotated; (B) the major
lipid classes in each category; and (C) the annotated polyunsaturated and (D) saturated and monounsaturated fatty acid
species. PC: phosphatidylcholine; PS: phosphatidylethanolamine; lysoP: lysophospholipids; MG: monoacyglycerols; DG:
diacyglycerols; TG: triacylglycerols. * Significantly different from the lean group; p < 0.05 (Mann–Whitney test).
Despite similar contents of fatty acyls (Figure 1A), some important long-chain n-3
polyunsaturated fatty acids varied between the groups (Figure 1C). Eicosapentaenoic acid
(EPA) and DHA abundance were, respectively, 1.74 and 2.20 times higher (p < 0.05) in
the obese group. Additionally, the mean value of AA was 2.5-fold higher in the obese
group, although the p-value did not reach statistical significance. Changes in free fatty
acids were restricted to essential polyunsaturated fatty acids, as contents of palmitic and
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stearic (saturated) and of palmitoleic and oleic (monounsaturated) acids were similar in
the lean and obese women (Figure 1D).
Maternal obesity is often associated with an inflammatory milieu and dyslipidemia.
Hence, the levels of IL-1 β, IL-6, IL-10, and TNF-α were measured in maternal blood,
placental tissue, and umbilical cord blood (Supplementary Figure S1). No differences
were found in any of these inflammatory markers, except for a lower content of IL-1
β in placentas from women with pre-gestational obesity. Likewise, the content of total
cholesterol, triacylglycerols, and HDL, LDL, and VLDL lipoproteins in maternal plasma
were similar between lean and obese women (Supplementary Figure S2).
These results suggest that placentas from women with pre-gestational obesity did
not present signs of overall lipid accumulation and no apparent signs of inflammation
nor maternal dyslipaemia were observed. However, placental polyunsaturated long-chain
fatty acids were increased.
3.3. Fatty Acid Transporter Protein FABP1 Is Decreased and Negatively Associated with
Polyunsaturated Fatty Acids in Placentas from Women with Pre-Gestational Obesity
We next analysed the fatty acid transporter proteins that handle unsaturated fatty acids
by the placenta: endothelial lipase (EL), fatty acid binding protein-1 (FABP1), and fatty acid
binding protein-3 (FABP3), at the protein and mRNA levels (Figure 2A,B). Placentas from
the obese group presented a significant 70% decrease in FABP1 protein content compared
with placentas from the lean group (p < 0.05) and a non-significant 30% decrease in mRNA
levels. Endothelial lipase and FABP3 protein and transcript levels were similar between
groups (Figure 2A,C).
The associations between the changes in FABP1 and polyunsaturated fatty acids
were assessed by Spearman rank correlations, and the ratios of fatty acid (FA) to FABP1
were also assessed (Figure 2C–G). For all n-3 fatty acids (Figure 2C–E) and n-6 fatty
acids (Figure 2F,G), the ratio FA:FABP1 was significantly higher in placentas from the
obese group. The ratios EPA:FABP1 (Figure 2E), DHA:FABP1 (Figure 2F), and AA:FABP1
(Figure 2G) were, respectively, 5.5-, 7-, and 6-fold higher in placentas from the obese
compared to the lean group. Spearman correlation analyses also showed that coefficients
were negative for all FA with statistically significant results for EPA (r = −0.82; p = 0.02;
Figure 2E) and marginally significant for DHA (r = −0.57; p = 0.09; Figure 2F) and AA
(r = −0.60; p = 0.054; Figure 2G). Taken together, these results suggest that FABP1 might
play a role in placental handling of these fatty acids and that the decrease in its content
might have an impact in the availability and signalling properties of EPA, DHA, and AA,
in particular.
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Figure 2. Fatty acid transporter protein FABP1 is decreased and negatively associates with long-chain polyunsaturated
fatty acids in placentas from women with pre-gestational obesity. Placentas from lean (•) and from obese (#) women
were compared according to placental fatty acid transporter proteins endothelial lipase, FABP1, and FABP3 at the protein
and transcript levels (A,B). The ratio of polyunsaturated fatty acids to FABP1 and the respective Spearman correlations
were calculated for the n-3 fatty acids α-linolenic (C), eicosapentaenoic (D), and docosahexaenoic (E), and for the n-6 fatty
acids linoleic (F) and arachidonic (G), to investigate possible associations between alterations in FABP1 and long-chain
fatty acid contents as a function of maternal pre-gestational obesity. * Significantly different from the lean group; p < 0.05
(Mann–Whitney test).
3.4. Neuroprostanes and Isoprostanes Are Increased and Negatively Associated with FABP1
Protein in Placentas from Women with Pre-Gestational Obesity
MicroLC–MS/MS targeted analysis identified seven products of non-enzymatic per-
oxidation of the essential polyunsaturated fatty acids DHA and AA in placental tissue.
Three DHA-derived neuroprostanes, namely 10(R)-10-F4t-NeuroP, 10(S)-10-F4t-NeuroP,
and 4(RS)-4-F4t-NeuroP, and four AA-derived isoprostanes, namely 15-epi-15-F2t-IsoP,
15-F2t-IsoP, 5(RS)-5-F2t-IsoP, and 5-F2c-IsoP (Figure 3A) were found. All neuroprostanes
and isoprostanes were increased (p < 0.05) in placentas from women with pre-gestational
obesity, except for 4(RS)-4-F4t-NeuroP, which was marginally increased (p = 0.07). The
overall increase of each DHA-derived neuroprostane was close to 2-fold, and of each
AA-derived isoprostane was near 1.7-fold. To investigate the combined behavior of these
fatty acids derived from DHA and AA, the sums of neuroprostanes and isoprostanes were
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compared between groups, and the same significant increase in placentas from women
with pre-gestational obesity was observed (Figure 3B).
Figure 3. Neuroprostanes and isoprostanes are increased and negatively associated with FABP1 protein in placentas
from women with pre-gestational obesity. Products of non-enzymatic peroxidation of the essential polyunsaturated fatty
acids docosahexaenoic (DHA) and arachidonic (AA) in placental tissue were analyzed by target microLC–MS/MS. Three
DHA-derived neuroprostanes (NeuroP) and four AA-derived isoprostanes (IsoP) were identified. Placentas from lean
women (•) and from obese women (#) were compared to investigate differences in DHA- and AA-derived isomers in
placentas from obese relative to lean women (A) and in the sum of neuroprostanes and isoprostanes (B). The ratio of
neuroprostane isomers to FABP1 and the respective Spearman correlations (C,D), and the ratio of isoprostanes to FABP1
and the respective Spearman correlations (E,F), were calculated to investigate possible associations between alterations in
FABP1 and DHA and AA non-enzymatic peroxidation as a function of maternal pre-gestational obesity. Possible differences
in the sources of neuroprostanes and isoprostanes induced by maternal pre-gestational obesity were assessed by the ratios
of neuroprostanes to free DHA (G) and to DHA-phosphatidylcholine species (PC; H), and isoprostanes to free AA (I) and to
AA-phosphatidylcholine species (PC; J). * Significantly different from the lean group; p < 0.05 (Mann–Whitney test).
We calculated the ratio of each neuroprostane and isoprostane to FABP1 (Figure 3C,E)
and performed correlation analyses (Figure 3D,F, respectively) following the same rationale
as used to investigate associations between DHA and AA with FABP1. Significantly higher
ratios of neuroprostanes and isoprostanes to FABP1 were found in placentas from obese
compared to lean women (p < 0.05). The neuroprostane to FABP1 ratios were nearly 6-fold
higher, and the isoprostanes to FABP1 ratios were nearly 5-fold higher in placentas from
obese women. Negative correlations were found between the sum of neuroprostanes and
isoprostanes and FABP1, but only the latter reached statistical significance (r = −0.42;
p = 0.17 for neuroprostanes, Figure 3D, and r = −0.66; p = 0.02 for isoprostanes, Figure 3F).
Taken together, these results suggest that the decrease in FABP1 protein observed in
placentas from women with pre-gestational obesity is, to some degree, associated with the
increase in neuroprostanes and isoprostanes observed in these placentas.
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The metabolic sources of DHA-derived neuroprostanes, in particular, and AA-derived
isoprostanes are not fully known; likely candidates are free DHA and AA, or phospho-
lipids, mainly phosphatidylcholine, enriched in these fatty acids [45]. To address this
issue, we calculated the ratios of neuroprostanes to free DHA (Figure 3G) and DHA-
enriched phosphatidylcholine species (Figure 3G,H), and of isoprostanes to free AA and
AA-enriched phosphatidylcholine species (Figure 3I,J). No significant differences were
observed in the ratios of neuroprostanes and isoprostanes to free FA between the lean
and obese groups. On the other hand, marginally lower ratios were observed for DHA-
enriched phosphatidylcholine species and AA-enriched phosphatidylcholine in placentas
from the obese compared to the lean group. These results suggest that DHA and AA in
phosphatidylcholine might be less susceptible to non-enzymatic peroxidation in placentas
from women with pre-gestational obesity. Non-esterified DHA and AA seem to similarly
contribute to the synthesis of neuroprostanes and isoprostanes, respectively, in placentas
from lean and obese women.
3.5. DHA-Derived Neuroprostanes and AA-Derived Isoprostanes Are Positively Associated with
Maternal Pre-Gestational BMI and Endothelial Lipase Protein; and DHA-Derived Neuroprostanes
Only Are Negatively Associated with Inflammation and Birth Weight
Spearman rank correlation was used to further investigate the associations of DHA-
derived neuroprostanes and AA-derived isoprostanes with inflammation and placental
lipid handling. Pre-gestational BMI (Figure 4A,C), endothelial lipase protein (Figure 4C,D),
maternal plasma TNF-α (Figure 4E,G), and placental TNF-α (Figure 4F,H) were considered
as independent variables. AA-derived isoprostanes, but not DHA-derived neuroprostanes,
significantly correlated with pre-gestational BMI (r = 0.60 and p = 0.04; r = 0.48 and p = 0.12,
respectively). Additionally, neuroprostanes (r = 0.64; p = 0.03) and isoprostanes (r = 0.78;
p = 0.01) significantly correlated with endothelial lipase protein. Correlations between
inflammation markers and oxidised fatty acids showed significant negative associations
between DHA-derived neuroprostanes and maternal (r = −0.81; p = 0.02) and placental
(r = −0.61; p = 0.04) TNF-α levels (Figure 4E,F). In contrast, no significant correlations
were found between AA-derived isoprostanes and inflammation markers, except for a
marginally significant negative correlation with placental TNF-α (r = −0.51; p = 0.09,
Figure 4H).
Figure 4. DHA-derived neuroprostanes are negatively correlated with inflammation markers, and AA-derived isoprostanes
are positively associated with maternal pre-gestational BMI. Spearman rank correlations of DHA-derived neuroprostanes
(NeuroP; A,B) and AA-derived isoprostanes (IsoP; C,D) and pre-gestational BMI and endothelial lipase, respectively, and
DHA-derived neuroprostanes (E,F) and AA-derived isoprostanes (G,H) and maternal and plasma TNF-α, respectively.
Placentas from lean women (•) and from obese women (#).
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Multiple regression analysis was used to investigate the tentative predictors of pla-
cental neuroprostanes and isoprostanes and their association with birth weight (Table 2).
The sum of placental DHA-derived neuroprostanes was predicted by pre-gestational
BMI (β = 1.64 × 102; positive association) and by placental TNF-α content, with negative
association (β = −5.56 × 103) (Table 2; model 1). The sole predictor of the sum of pla-
cental AA-derived isoprostanes was placental endothelial lipase protein (β = 1.21 × 104;
model 2). Most importantly, birth weight was significantly determined by pre-gestational
BMI (β = 1.26 × 102), gestational weight gain (β = 7.72 × 101), and by the sum of placental
neuroprostanes, with a negative association (β = −4.06 × 10−1) (Table 2, model 3).
Table 2. Multiple regression models for the assessment of predictors of placental Σ neuroprostanes and Σ isoprostanes and












Pre-gestational BMI 1.64 × 102 2.61 × 101 0.0004
93.88 20.1 0.0000TNF-α, placenta −5.56 × 103 1.59 × 103 0.0101
Gestational weight gain — — ns — — ns
IL-6, placenta — — ns — — ns
Endothelial lipase, protein — — ns — — ns




Endothelial lipase, protein 1.21 × 104 1.12 × 103 0.0000 93.65 22.9 0.0000
Pre-gestational BMI — — ns — — ns
Gestational weight gain — — ns — — ns
TNF-α, placenta — — ns — — ns
IL-6, placenta — — ns — — ns
Birth weight
Model 3
Pre-gestational BMI 1.26 × 102 1.38 × 101 0.0001
99.07 6.83 0.0000Gestational weight gain 7.72 × 101 1.71 × 101 0.0040
Σ Neuroprostanes, placenta −4.06 × 10−1 1.37 × 10−1 0.0253
Σ Isoprostanes, placenta — — ns — — ns
IL-6, placenta — — ns — — ns
TNF-α, placenta — — ns — — ns
Endothelial lipase, protein — — ns — — ns
1 Estimated relative error of estimate = (estimated absolute error × 100%)/average value of the dependent variable; 2 Model significance.
Significant associations were independent of the following variables, denoted as non-significant (ns) p-values: model 1, gestational weight
gain, IL-6 (placenta), endothelial lipase protein (placenta), and FABP1 (placenta); model 2, pre-gestational BMI, gestational weight gain,
TNF-α (placenta), and IL-6 (placenta); model 3, Σ of isoprostanes (placenta), interleukin-6 (placenta), TNF-α (placenta), and endothelial
lipase protein (placenta);—blank cell; IL-6: Interleukin-6; TNF-α: Tumour Necrosis Factor-α.
Collectively, DHA-derived neuroprostanes might mediate a less inflammatory re-
sponse and potentially prevent excessive neonatal weight gain, as opposed to AA-derived
isoprostanes, which appeared related to increased maternal adiposity.
4. Discussion
In this study, we show that despite no overall features of lipid accumulation, placentas
from women with pre-gestational obesity contain an increased content of polyunsaturated
free fatty acids. This increase is associated with a decreased content of FABP1, a cytoplas-
mic protein that handles unsaturated fatty acids and is important for determining their
biological fate. Additionally, higher contents of neuroprostanes and isoprostanes, which
are products of non-enzymatic oxidation of DHA and AA, respectively, were observed in
placentas from obese women. Correlation and multivariate analyses suggested that these
oxidised fatty acids are associated with maternal and placental inflammation, and also
with birth weight. To our knowledge, this is the first report to characterize DHA-derived
neuroprostanes and AA-derived isoprostanes in the human placenta, and in particular to
explore their role in maternal and neonatal outcomes in the context of obesity.
Obesity in general is associated with chronic low-grade inflammation and insulin
resistance. Therefore, obese women are at higher risk of developing metabolic disturbances
during pregnancy [1]. In this study, samples from women who developed gestational
Nutrients 2021, 13, 2768 12 of 18
diabetes mellitus, pre-eclampsia, or other complications were excluded from the analysis.
Therefore, one of the strengths of our study is the well characterized patient cohort and
the homogeneity of placental samples which reduced possible confounders of obesity-
associated comorbidities. The median BMI value of the obese women was 34.3, indicating
they present obesity class 1, and only one out of six women presented with a BMI of
37.6 (obesity class II). Additionally, a non-significant 40% decrease in gestational weight
gain was observed in obese women. This result is in agreement with previous reports
showing that obese women gain less weight than lean women during pregnancy [30]. The
mechanisms involved are not well established, but it might be a physiological response to
compensate for the excess stored energy. In our study, we found similar energy and nutrient
intake between lean and obese women, possibly as a result of the nutritional counseling they
received during the pre-natal care. The fact that the obese women did not present with other
metabolic complications might explain the similar plasma concentrations of inflammatory
markers, and lipoproteins and triacylglycerols as in lean women. We speculate, therefore,
that despite being obese, they were metabolically healthy, and this may explain the lack
of differences in placental weight and efficiency. Although several studies have shown
that maternal obesity is associated with an inflammatory and pro-oxidant milieu [46,47],
there are reports of healthy obese mothers with no signs of dyslipidaemia [13,48]. Indeed,
a lower content of IL-6 and reduced infiltration of macrophages in placentas from obese
women was recently shown [49]. Conversely, there are consistent data showing that several
placental responses appear to be affected by maternal pre-gestational obesity, irrespective
of its severity [16,50].
The placenta is the highly specialized organ that interfaces between the mother and
her baby. It integrates signals of maternal availability and fetal demand of nutrients and
oxygen, and has a central role in determining the life-long health of the offspring [51].
The importance of placental lipid metabolism in regulating maternal-fetal transfer of
fatty acids, in particular essential polyunsaturated fatty acids, has been recognized in
healthy pregnancies [14,52] and in pre-gestational obesity [17,18], although the mechanisms
involved are not fully known. Indeed, in this study, we showed that placentas from
women with pre-gestational obesity contain a significant increase in DHA and EPA content
compared to placentas from lean women. Additionally, the median value of placental AA
from obese women was nearly 2.5-fold higher than the lean group, despite these differences
being non-significant statistically, which may reflect the small sample size.
Alterations in placental fatty acid transporter proteins are plausible mechanisms
associated with altered placental lipid handling in maternal pre-gestational obesity [53].
Indeed, we show that FABP1 is decreased in placentas from obese women, corroborating a
previous study [25]. The decrease in FABP1 in placentas from the obese group was reflected
in significantly higher ratios of n-3 and n-6 polyunsaturated fatty acids to FABP1.
FABP1 is the liver isoform of FABP. Unlike other members in the FABP family, it has
two ligand-binding sites for fatty acids and higher affinity for long-chain unsaturated
fatty acids. Besides fatty acids, FABP1 binds a range of hydrophobic molecules, such
as peroxisome proliferator-activated receptors (PPARs), prostaglandins, hydroxyl and
hydroperoxyl metabolites of AA, lysophopholipids, and pro-oxidants such as heme [54].
FABP1 has been found in the cytosol, nucleus, and mitochondria [55,56], and so may have
multiple roles. Hence, we speculate that the decreased content of FABP1 found in placentas
from women with pre-gestational obesity might have affected placental function beyond
just lipid transport.
Due to the role of FABP1 in trafficking fatty acids to the nucleus and also its ability
to bind PPARs, the decrease in placentas from women with pre-gestational obesity likely
altered pathways related to placental lipid handling and fatty acid metabolism. There is
evidence that PPARs are involved in these processes in the human placenta [57,58]. Similar
contents of PPARs in placentas from obese and lean women [25] were described in parallel
with increased PPAR-γ (related to fatty acid synthesis) and decreased PPAR-α (related to
fatty acid oxidation) [20]. Yang et al. have proposed that regulation of PPARs is important
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at the maternal–fetal interface and this fact might explain the apparent discrepancies in
PPARs content in maternal pre-gestational obesity [59]. It remains to be determined if and
how PPARs participate in the cross-talk between long chain polyunsaturated fatty acids
and FABP1 protein seen in the present study.
As FABP1 binds to pro-oxidant molecules and is considered an antioxidant, at least in
the liver [54], its decrease might render the placenta more susceptible to oxidative stress
in obese women. A decreased total antioxidant capacity and increased activation of the
pro-oxidant NFkB pathway has been observed in placentas from women with obesity [60].
The significant increase in DHA-derived neuroprostanes and AA-derived isoprostanes we
observed supports a pro-oxidant milieu in placentas from the obese group. In addition to
increased concentrations of neuroprostanes and isoprostanes, we found that their ratios
to FAPB1 were also significantly altered, and that FABP1 negatively correlated with the
total isoprostanes. These results not only support the concept of a pro-oxidant milieu, but
also suggest that FABP1 binds to isoprostanoids, in particular AA-derived isoprostanes, as
observed for enzymatically derived fatty acid mediators.
Neuroprostanes and isoprostanes are isoprostanoids (isomers of prostaglandins),
formed by the non-enzymatic peroxidation of DHA and AA, respectively. They have
been described as important signalling molecules, and AA-derived isoprostanes act in
vascular smooth muscle through tyrosine kinase and Rho kinase in human cells [61] and
through prostanoid receptors in rats [62]. AA-derived isoprostanes are implicated in
cardiovascular diseases acting as vasoconstrictors and considered markers of oxidative
stress [45]. Conversely, recent evidence suggests that DHA-derived neuroprostanes have
anti-inflammatory properties [63,64], despite the fact that they have been implicated in
oxidative stress in neurodegenerative diseases [65]. Their role in placental function in
pregnancies complicated by maternal obesity has not yet been described.
Oxidised 9-HODE, 13-HODE, and 15-HETE, products of AA produced by cycloxyge-
nase activity, did not affect expression of syncytin, cyclin E, and p27, which are markers of
trophoblast differentiation, indicating that they are not implicated in trophoblast dysfunc-
tion, at least in healthy trophoblasts [66]. On the other hand, in placentas from pregnancies
complicated with pre-eclampsia, it has been shown that F2 class isoprostanes derived from
AA contribute to oxidative stress and have vasoconstrictive properties [67].
The formation of isoprostanoids is regulated to some extent, and are predominantly
formed in situ from oxidation of DHA or AA esterified to phosphatidylcholine in cell mem-
branes. Therefore, their signalling properties depend upon phospholipase A2 activity [45],
and a strict correlation between placental phospholipase A2 mRNA and free F2-isoprostane
levels has been found in pre-eclampsia [67].
Our marginally lower ratios of neuroprostanes to DHA-enriched and of isoprostanes
to AA-enriched PC in placentas from obese women suggest that the proportion of these
mediators formed in situ is decreased in obesity. The significance of this result may be re-
lated to compensatory mechanisms in placentas from obese women, controlling membrane
function and avoiding excessive release of mediators and possibly controlling neonatal
birth weight. Indeed, increased placental phospholipase A2 activity has been correlated
with increased placental accumulation of lipids and adiposity in the newborn [68].
In the present study, AA-derived isoprostanes correlated with maternal pre-gestational
BMI. Additionally, in the multivariate model, the sole predictor of isoprostanoids in the
placenta was placental EL protein. These results could be interpreted in the light of the
pro-inflammatory effect of AA-derived isoprostanes. A higher content of EL has been
described in placentas from pregnancies complicated with gestational diabetes mellitus, in
addition to obesity [69]. Consistent with these findings, we observed a non-statistical 25%
increase in EL in placentas from women with pre-gestational obesity.
In the case of neuroprostanes, multivariate models indicated that both maternal pre-
gestational BMI (positive β coefficient) and placental TNF-alpha (negative β coefficient)
were tentative predictors of their content in the placenta, suggesting their possible anti-
inflammatory role. This association was also observed in the correlation analysis, where
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the sum of neuroprostanes was negatively correlated with maternal and placental TNF-α
contents. Importantly, when we evaluated the possible involvement of neuroprostanes
and isoprostanes with birth weight, total neuroprostanes presented a negative contri-
bution and, as expected, pre-gestational BMI and gestational weight gain had positive
associations. However, total isoprostanes did not fit the same experimental model. These
results suggest that neuroprostanes present anti-inflammatory roles in placentas from
women with pre-gestational obesity, and by negatively affecting birth weight might at-
tenuate the intergenerational cycles of detrimental effects on metabolic health as the risk
of overweight/obesity in childhood increases gradually over the full range of maternal
pre-gestational BMI [70]. Indeed, neonatal birth weight was similar between groups in the
present study.
A word of caution is necessary when investigating birth weight in the context of
gestational obesity as it has been suggested that neonatal adiposity, and not total weight, is
independently associated with childhood adiposity [71]. The association between placental
oxidised fatty acids and neonatal outcomes, including adiposity, has never been addressed.
An additional possible mechanism by which neuroprostanes exert anti-inflammatory effects
is the observation that 4-(RS)-4-F4t-NeuroP increased mRNA levels of the enzyme heme-
oxygenase, which degrades heme, in human neuroblastoma cells and in primary culture of
neurons [65]. Given the fact that FABP1 is able to bind heme, a molecule with pro-oxidant
properties, the increase in neuroprostane isomers might counteract the decrease in FABP1
protein in the obese group, providing a means of anti-oxidant defense. It remains to be
determined if this is the case in the term human placenta in maternal pre-gestational
obesity.
The main limitation of the present study is the sample size, which impacts on the
statistical power. Consequently, results from the multiple regression analyses should be
considered as an approach to screen for predictors in each model. In addition, we were
not able to address sexually dimorphic responses in placental fatty acid metabolism. This
aspect is important as a recent study showed that placentas from females appear more
prone to store and esterify fatty acids, while placentas from males have a decreased capacity
to transfer DHA to cord blood [72]. Nonetheless, our data are biochemically sound and
bring new knowledge to the field, identifying isoprostanoids as potential novel mediators
of placental function.
As maternal diet is the ultimate source of DHA and AA, our results add to the body
of evidence that there must be a balance between intake of n-3 and n-6 fatty acids, and
possibly a higher intake of DHA is necessary during pregnancy [73]. A recent pilot trial
demonstrated that DHA supplementation starting early in pregnancy promoted higher
lean mass accrual at birth and improved fetal growth [74]. The next step is to evaluate the
intake of individual fatty acids and also to address the quality of the diet of these mothers
by assessing other factors, e.g., dietary antioxidants, that contribute to placental lipid
handling in a larger cohort. Intervention studies are also needed to identify the molecular
mechanisms involved. Such data would form the basis of efficient dietary strategies to
decrease the burden of maternal pre-gestational obesity.
5. Conclusions
The decreased content of FABP1 and increased content of DHA, EPA, and AA in
placentas from women with pre-gestational obesity indicate important alterations in pla-
cental lipid metabolism and fatty acid handling even in obese women that did not present
major signs of inflammation. Additionally, the decrease in FABP1 content was associated
with increased contents of DHA-derived neuroprostanes and AA-derived isoprostanes in
placentas from obese women. Distinct mechanisms seemed to contribute to their increased
content, as total DHA-derived neuroprostanes was negatively associated with placental
TNF-α, and AA-isoprostanes associated with pre-gestational BMI. Importantly, placen-
tal neuroprostanes negatively contributed to birth weight. Taken together, these results
confirm previous observations showing that placental lipid metabolism is disrupted in
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maternal obesity. The possibility that these oxidised fatty acids act as mediators of placental,
and possibly maternal, inflammation opens several possibilities for the investigation of the
molecular mechanisms associated with alterations in placental fatty acid metabolism in
maternal pre-gestational obesity and their possible role in the health of the offspring.
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